Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity
Journal of Pharmaceutical Analysis · 2026-11 · 101839
DOI: 10.1016/j.jpha.2026.101839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-11. Verfasst von Yihua Zhang und 13 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zhang, Y., Shao, Y., Zhang, L., Ren, S., Lu, D., Zhang, H., Qian, X., Chen, Y., Yang, Y., Zhu, J., Zeng, Y., Wang, S., Yan, Z., & Liu, Z. (2026). Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity. Journal of Pharmaceutical Analysis, 101839. https://doi.org/10.1016/j.jpha.2026.101839
Vancouver
Zhang Y, Shao Y, Zhang L, Ren S, Lu D, Zhang H, et al. Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity. Journal of Pharmaceutical Analysis. 2026:101839. doi:10.1016/j.jpha.2026.101839
BibTeX
@article{Zhang2026,
author = {Zhang, Yihua and Shao, Yuna and Zhang, Liying and Ren, Shihang and Lu, Di and Zhang, Huiling and Qian, Xinyu and Chen, Yuling and Yang, Yang and Zhu, Jianjie and Zeng, Yuanyuan and Wang, Shengjie and Yan, Zhaowei and Liu, Zeyi},
title = {Repurposing cadazolid as a CBLB-dependent non-PROTAC FAK degrader to suppress lung adenocarcinoma and restore EGFR-TKI sensitivity},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
pages = {101839},
doi = {10.1016/j.jpha.2026.101839}
}
EUVIMED